HER2 Nanoparticle Safety and Specificity Data Presented at AACR 2019

Marie Zhang, PhD, Vice President of Research and Clinical Development at Imagion Biosystems, presented the poster "HER2 Functionalized Nanoparticles Are Safe…


MagSense™ Pre-Clinical Study Presented at 2018 SABCS

On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster "Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles" at…


MagSense™ Technology at ASCO 2018 Annual Meeting

The ASCO 2018 Annual Meeting abstract, "Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic…


MagSense™ Pre-Clinical Safety Data from AACR 2018

Pre-clinical data on Imagion Biosystems' MagSense HER2+ cancer detection platform have shown: specific binding and detection of HER2+ tumor cells in vitro…


Late-Breaking MagSense™ Safety Study Abstract Accepted for AACR 2018

Imagion Biosystems' abstract "Detection of HER2+ tumor cells using MagSense™ nanoparticles: safety and sensitivity" has been accepted for the 2018 AACR meeting…


Imagion Biosystems at BIO 2017

The 2017 International Convention of BIO, the Biotechnology Innovation Organization, was held June 19-22 in San Diego. More than 16,000 individuals attended…


Tumor Detection Study Presented at "Frontiers in Biomagnetic Particles" Conference

On June 5, 2017, Imagion Biosystems Chief Scientist Erika Vreeland, PhD, presented the results of a collaborative tumor detection study to the scientific…


Magnetic Relaxometry at AACR 2017

This year's Annual Meeting of the American Association for Cancer Research was held April 1-5 in Washington, D.C. The theme of this year's meeting was…